Natural immune regulation of activated cells
Donna A. Chow,Ricky Kraut,Xiaowei Wang
DOI: https://doi.org/10.1016/S1567-7443(01)80029-6
2001-01-01
Abstract:The natural immune system provides a prompt first-line of defense against invading pathogens. It is comprised of both cellular and humoral mediators including macrophages, NK and T cells, natural antibodies, complement and interferon. Unlike the exquisitely specific, adaptive immune system, natural immunity is polyspecific, recognizing highly conserved homologous or crossreactive epitopes (homotopes), and does not require previous exposure to antigen to generate a response. This evolutionarily conserved, innate system is also considered important in homeostatic regulation of the organism through a highly connected receptor network and through the removal of aberrant cells, including nascent tumor cells. It provides the immunological environment for the development of the adaptive T cell response. Furthermore, activation of the acute phase response (APR) through immune derived cytokines when adaptive immunity has failed to eradicate an invader, provides a massive stimulus to the natural immune system including the polyspecific acute phase mediators in an all-out final natural defense. Several in vivo and in vitro syngeneic murine tumor models of natural resistance haveprovided evidence to support polyclonal natural antibody (NAb), NK cell and activated macrophage surveillance of developing tumors. A study of NAb, those antibodies in the circulation of normal individuals that are not intentionally immunized, revealed a consistent inverse correlation between NAb binding by tumors and tumor incidence in a threshold s.c. tumor inoculum assay of natural resistance. Considering that LPS induces APR, a role for neuroendocrine regulation of NAb surveillance was suggested by correlating LPS-induced increases in NAb levels and reductions in tumorigenicity of threshold s.c. inocula of an NK-resistant tumor. Furthermore, a strong influence of sex hormones on the natural resistance was evident in the reduced tumor incidence of threshold s.c. tumor inocula in female versus male mice. T lymphomas treated with the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) to generate variants and repeatedly selected for high serum NAb IgG- plus IgM-binding, exhibited a reduced s.c. tumorigenicity. Surface expression analysis also revealed that the selected cells bound more monoclonal antibodies against activation-associated molecules including CD25, the IL2-Rα chain, and asialo forms of CD45RA, a transient marker of T cell activation. This argues that NAb also regulates T cell activation. The observations in the murine models raised the possibility that direct down-regulation ofT cell activation may contribute to the beneficial effects of intravenous immunoglobulin (IVIg) against inflammatory and autoimmune diseases. In order to identify the T cell surface targets of IVIg in humans, we produced a model human T cell through TPA treatment of Jurkat T leukemia cells with repeated selection for high serum IgG- plus IgM-binding which mimics the conditions for IVIg action in patients. Cells produced from the 3rd and 4th sequential selections exhibited stable increases in serum IgG- and IgM-binding of 28% for J3.1 and 45% for J4.1. The J4.1 bound at least 45% more IVIg than the parental cells consistent with their increased binding of pooled human IgG-plus IgM. The J4.1 exhibited a 120% increase in expression of CD45RA, a marker which correlates with cytokine and hormone expression in women. The results provide the first evidence that human serum natural IgG-plus IgM antibodies and IVIg react with a CD45RA epitope. The conserved nature of many NAb and the contribution of endogenous NAb and passively administered IVIg to the control of immune activation within the context of neuroendocrine regulation, raise the possibility that the epitope on CD45RA may be a highly conserved homologous epitope or homotope of the neuroimmune system involved in health and disease.